ABT-418

ABT-418 is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It binds with high affinity to the α4β2, α2β2 and α7 subtypes, but not to the α3β4 subtype. It has nootropic, neuroprotective and anxiolytic effects,   and has been researched for treatment of both Alzheimer's disease and more recently ADHD. ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.